Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal

Why is DoorDash adding payment plans? What drives Poland’s tech tax proposal? How does Heathrow closure affect revenue? What spurred Portugal’s early election call? Why did NewJeans lose legal battle? How will Manus boost China’s AI sector? Why did Elon Musk sue India's government? How does EU unity affect market stability? What underlies UK red tape concerns?

Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal

benzinga.com/general/biotech/25/03/44418639/sanofi-strengthens-its-immune-system-focused-pipeline-with-around-2-billion-dren-bio-deal

Sanofi SA (NASDAQ:SNY) on Thursday agreed to acquire Dren Bio Inc.’s DR-0201, a targeted bispecific myeloid cell engager (MCE).
DR-0201 is a CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce B-cell depletion via…

This story appeared on benzinga.com, 2025-03-20 14:42:52.